

---

## Medivir Q2 2024 - Licensing Deal after ESMO?

Redeye comments on Medivir's Q2 report. The main event in the quarter was the presentation of an estimated mean TTP of 10.8 months for fostrox in liver cancer. The next catalyst will be updated fostrox data at ESMO in mid-September.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Medivir Q2 2024 - Licensing Deal after ESMO?](#)